Patents Assigned to Elan Pharmaceuticals
  • Method of Measuring Amyloid-Beta Peptides
    Publication number: 20090123952
    Abstract: The present invention relates to methods for measuring A? peptides in a sample, particularly a sample of blood, such as whole blood and plasma, and to methods of determining whether a compound alters the amount of A? produced by a cell or animal.
    Type: Application
    Filed: November 14, 2005
    Publication date: May 14, 2009
    Applicants: PFIZER, INC., ELAN PHARMACEUTICALS
    Inventor: John Randall Slemmon
  • Compounds to treat Alzheimer's disease
    Patent number: 7214715
    Abstract: The present invention is substituted amines of formula (X) and of the formula (X?) useful in treating Alzheimer's disease and other similar diseases.
    Type: Grant
    Filed: June 29, 2001
    Date of Patent: May 8, 2007
    Assignees: Pharmacia & Upjohn, Elan Pharmaceuticals
    Inventors: James P. Beck, Lawrence Y. Fang, John N. Freskos, Andrea Gailunas, Roy Hom, Barbara Jagodzinska, Varghese John, Michel Maillard, Shon R. Pulley, Ruth E. TenBrink
  • Test and model for Alzheimer's disease
    Publication number: 20030165958
    Abstract: Model systems of Alzheimer's disease comprise a DNA sequence encoding an amyloid precursor protein (APP) isoform or fragment that has an amino acid substitution. The substituted amino acid may be other than valine at the amino acid position corresponding to amino acid residue position 717 of APP770. Methods of determining genetic predisposition to Alzheimer's disease are also disclosed.
    Type: Application
    Filed: February 3, 2003
    Publication date: September 4, 2003
    Applicant: Elan Pharmaceuticals
    Inventors: John Anthony Hardy, Marie-Christine Chartier-Harlin, Alison Mary Goate, Michael John Owen, Michael John Mullan
  • Methods and compositions for monitoring cellular processing of beta-amyloid precursor protein
    Patent number: 6018024
    Abstract: Processing of .beta.-amyloid precursor protein (.beta.APP) is monitored by detecting the secretion of a soluble .beta.APP fragment resulting from cleavage of .beta.APP at the amino-terminus of .beta.-amyloid peptide. In vivo monitoring of secretion of the .beta.APP fragment may be monitored for diagnosis and prognosis of Alzheimer's disease and other .beta.-amyloid-related diseases, while in vitro monitoring of such secretion from cultured cells may be monitored to identify inhibitors of .beta.-amyloid production. The .beta.APP fragment may be detected using antibodies and other specific binding substances which recognize a carboxy-terminal residue on the fragment.
    Type: Grant
    Filed: May 1, 1997
    Date of Patent: January 25, 2000
    Assignee: Elan Pharmaceuticals
    Inventors: Peter A. Seubert, Dale B. Schenk, Lawrence C. Fritz